« The symptom of lung cancer: Lung cancer is inchoate symptom, lung cancer is terminal symptom. | Main | What is existence of lung cancer cure in non-standardly? — the remedial method of lung cancer mistake | The plan of a few mistakes that lung cancer treats. »
Lung cancer of inchoate blame cellule is newest cure makes progress. — inchoate | Blame cellule | Lung cancer | Cure
By admin | June 10, 2008
On conference of lung cancer of area of the 2nd Asia-Pacific, expert of very much domestic and international famous lung cancer, include Guangdong to visit people hospital Masahiro Tsuboi teachs surgery of tumour of bosom of medical university of Tokyo of internal medicine of tumour of center of tumour of Germany of hospital of university of Duisburg-Essen of Professor Wu Yilong, Germany Professor Wilfried Eberhardt, Japan and Professor Hisao Asamura waits for surgery of bosom of center of Japanese national cancer, lung cancer of cellule of inchoate blame (the comprehensive treatment of NSCLC) made wonderful presentation.
Professor Wu Yilong reported ” can excise lymph node of mediastinum of NSCLC travel systematization to sweep (the random and clinical trial of SND) ” result. Should study the analysis of pair of 471 NSCLC patients shows, the recrudescent rate of these patients is 3.8% , move rate is 26.5% , 5 far move is the person that the main reason; that brings about its operation to treat failure accepts SND years total survival rate is 48.37% , accept method of sampling of mediastinum lymph node only (MLS) person 5 years total survival rate is 36.98% , two groups of patients have significance difference. Manser brings into 11 clinical trials when wait to was published 2005 (in all patient of 1910 inchoate NSCLC) also point out in assemble analysis, SND should become the standard that can excise NSCLC patient to treat mode.
Professor Tsuboi introduced thorax lens operation and TV to assist thorax lens operation (VATS) gets used to card in the application of pectoral surgery, and this plants VATS small the actor defect that achieves a technology. Particularly of fetching attention is, professor Tsuboi is in a hospital already robot surgery technology as VATS outspread, in introducing pectoral surgery operation. This announced the development trend of prospective bosom surgery and direction.
Change about assisting cure and new auxiliary change cure to be in the applied respect of inchoate NSCLC patient, the Ⅲ that patient of A period NSCLC applies the Ⅲ of B~ of a Ⅰ that Professor Wu Yilong reported in Guangdong center of tumour of province people hospital undertakes to much sitar is surpassed and block platinum to undertake assisting changing cure jointly period clinical trial — CSLC0201(TAX-210) research result. This research still discussed β - Tublin Ⅲ is in the value in forecasting much sitar to surpass sensitivity. The result shows, the group that change cure and pure surgery team assist after art to tumor progress time (TTP) does not have β of significance difference; - Tublin Ⅲ is electropositive person with β - Tublin Ⅲ is electronegative person live without disease period (DSF) has significance difference (P=0.006) . The conclusion of this research is: Of patient of SCLC of 狽 of Chi of spoon of bottle of ㄖ individual turn treatment mode; is new auxiliary change cure to still exist to the action of NSCLC controversy; is auxiliary change cure and new assisting the contrast that changes cure is the serious content that will study henceforth.
Professor Eberhardt also reported Europe assists 3 when change cure clinical research about inchoate NSCLC — ALPI, IALT and the result that ANITA studies. ALPI research is Europe is in the first when undertake after complete resection in inchoate NSCLC patient assist large-scaly change cure clinical trial. This research shows, with platinum kind the NSCLC patient after the auxiliary plan changing cure that is a foundation applies to an operation to excise, but do not support MVP plan (silk cracks mildew element + Changchun ground laborious + suitable platinum) as the auxiliary plan that change cure. The NSCLC patient after IALT considers to support an operation to excise uses the plan that is a foundation with arranging platinum to undertake assisting changing cure. ANITA considers to show, with platinum kind those who be a foundation is auxiliary the NSCLC patient after changing cure to apply to an operation to excise.
Current, europe’s large-scale Ⅲ period the inchoate NSCLC patient after clinical trial already entered resection of group of more than 4000 completeness in all. The result of these research confirms, after art with platinum kind the total survival rate that can improve a patient significantly for the auxiliary plan of the foundation that change cure, patient 5 years the improvement of survival rate studies from 4.1%(IALT) study to 15%(NCIC) differ.
Topics: lung cancer |